ClinicalTrials.gg

Program

HLX3902

A development code.

In Fosun Pharma's pipeline, STEAP1 x CD3 x CD28. Its studies are led by Fosun Pharma.

Furthest: phase 1, since Apr 2, 20261 company-led study, 1 open or runningNext primary completion: Jun 29, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Fosun Pharma11 open or runningphase 1since Apr 2, 2026Apr 2, 2026Jun 29, 2027phase 1 · NCT07533708
  • Named in Fosun Pharma’s own pipeline as HLX3902 (STEAP1 x CD3 x CD28), phase 1, as of Sep 21, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 2, 2026First study: phase 1 study in mCRPC or Advanced/Metastatic Solid TumorsFirst studyNCT07533708 · 48 planned · China

Ahead

  1. Jun 29, 2027Primary completion: phase 1 study in mCRPC or Advanced/Metastatic Solid TumorsNCT07533708

TargetBeta

“STEAP1 x CD3 x CD28”the company's pipeline, read by Claude · source

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07533708mCRPC or Advanced/Metastatic Solid Tumors · China1RecruitingJun 29, 202748

How it is read

Names in the registry

  • “HLX3902”, 1 entry

Codes read as this program: HLX3902.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.